Related references
Note: Only part of the references are listed.Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy
Chun Li et al.
BLOOD (2009)
Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period
M. Teichert et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
P. Borgiani et al.
PHARMACOGENOMICS (2009)
CYP4F2 genetic variant alters required warfarin dose
Michael D. Caldwell et al.
BLOOD (2008)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
The RIZ Pro704 insertion-deletion polymorphism, bone mineral density and fracture risk:: The Rotterdam study
Lisette Stolk et al.
BONE (2008)
Estimation of the multiple testing burden for genomewide association studies of nearly all common variants
Itsik Pe'er et al.
GENETIC EPIDEMIOLOGY (2008)
VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients
Christos N. Markatos et al.
PHARMACOGENOMICS (2008)
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation:: A prospective randomized controlled study
Y. Caraco et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation
Jeffrey L. Anderson et al.
CIRCULATION (2007)
The Rotterdam Study: Objectives and design update
Albert Hofman et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2007)
Identifying the genotype phenotype:: a role model behind the found in VKORC1 and its association with warfarin dosing
Dana C. Crawford et al.
PHARMACOGENOMICS (2007)
Association of warfarin dose with genes involved in its action and metabolism
Mia Wadelius et al.
HUMAN GENETICS (2007)
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose:: a prospective study
John F. Carlquist et al.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2006)
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status:: Interaction between both genotypes affects overanticoagulation
Tom Schalekamp et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients
R Montes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P4502C9 gene polymorphisms on warfarin dose requirements
CL Aquilante et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:: proposal for a new dosing regimen
EA Sconce et al.
BLOOD (2005)
A C1173T dimorphism in the VKORC1 gene determines coumarin Sensitivity and bleeding risk
PH Reitsma et al.
PLOS MEDICINE (2005)
Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity
L Bodin et al.
BLOOD (2005)
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
MJ Rieder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin
G D'Andrea et al.
BLOOD (2005)
Comparative pharmacokinetics of vitamin K antagonists - Warfarin, phenprocoumon and acenocoumarol
M Ufer
CLINICAL PHARMACOKINETICS (2005)
The risk of overanticoagulation in patients with cytochrome P450CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon
LE Visser et al.
PHARMACOGENETICS (2004)
Cytochrome P450 ω-hydroxylase pathway of tocopherol catabolism -: Novel mechanism of regulation of vitamin E status
TJ Sontag et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Share Paper
